Table 1.
Characteristics of patients included in this study
| Characteristics | No. of patients/No. of all patients | Percentage |
|---|---|---|
| No. of patients | 7425/7425 | 100.0% |
| Average Median Age (range) | 65.1 (25 to 87) | |
| Sex | ||
| Male | 3955/6912 | 57.2% |
| Female | 2957/6912 | 42.8% |
| ECOG score | ||
| 0–1 | 4496/5083 | 88.5% |
| 2+ | 587/5083 | 11.5% |
| Site | ||
| Head or neck | 1895/4209 | 45.0% |
| Body or tail | 2037/4209 | 48.4% |
| Other* | 277/4209 | 6.6% |
| Metastatic diseases | 6684/7425 | 90.0% |
| Metastatic sites | ||
| Liver | 1825/3213 | 56.8% |
| Lymph nodes | 511/3213 | 15.9% |
| Peritoneal | 572/3213 | 17.8% |
| Lung | 446/3213 | 13.9% |
| Other | 401/3213 | 12.5% |
| Treatments | ||
| FOLFIRINOX | 2659/6351 | 41.9% |
| GEM-NAB | 1929/6351 | 30.4% |
| GEM | 1420/6351 | 22.4% |
| mFOLFIRINOX | 343/6351 | 5.4% |
Abbreviations: No.: number; ECOG: Eastern Cooperative Oncology Group; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX
* Including the cancers involved multiple sites or those originating from unknown subsites of pancreas